• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

古今中外:提示一个核心转录后网络驱动卵巢癌化疗耐药。

Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer.

机构信息

Department of Oncology, University of Oxford, Oxford, UK.

出版信息

Wiley Interdiscip Rev RNA. 2018 Jan;9(1). doi: 10.1002/wrna.1432. Epub 2017 Aug 1.

DOI:10.1002/wrna.1432
PMID:28762650
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5763387/
Abstract

RNA-binding proteins (RBPs) and noncoding (nc)RNAs (such as microRNAs, long ncRNAs, and others) cooperate within a post-transcriptional network to regulate the expression of genes required for many aspects of cancer behavior including its sensitivity to chemotherapy. Here, using an RBP-centric approach, we explore the current knowledge surrounding contributers to post-transcriptional gene regulation (PTGR) in ovarian cancer and identify commonalities that hint at the existence of an evolutionarily conserved core PTGR network. This network regulates survival and chemotherapy resistance in the contemporary context of the cancer cell. There is emerging evidence that cancers become dependent on PTGR factors for their survival. Further understanding of this network may identify innovative therapeutic targets as well as yield crucial insights into the hard-wiring of many malignancies, including ovarian cancer. WIREs RNA 2018, 9:e1432. doi: 10.1002/wrna.1432 This article is categorized under: RNA Interactions with Proteins and Other Molecules > Protein-RNA Interactions: Functional Implications Translation > Translation Mechanisms RNA in Disease and Development > RNA in Disease.

摘要

RNA 结合蛋白(RBPs)和非编码(nc)RNAs(如 microRNAs、长 ncRNAs 等)在转录后网络中合作,共同调节基因的表达,这些基因对于癌症行为的许多方面都很重要,包括对化疗的敏感性。在这里,我们采用以 RBP 为中心的方法,探索了当前关于卵巢癌中转录后基因调控(PTGR)贡献者的知识,并确定了一些共同点,这些共同点暗示存在一个进化上保守的核心 PTGR 网络。该网络在当代癌细胞的背景下调节生存和化疗耐药性。有新的证据表明,癌症的生存依赖于 PTGR 因子。进一步了解这个网络可能会确定创新的治疗靶点,并为许多恶性肿瘤(包括卵巢癌)的固有机制提供关键的见解。WIREs RNA 2018, 9:e1432. doi: 10.1002/wrna.1432 本文属于以下类别: RNA 与蛋白质和其他分子的相互作用 > 蛋白质-RNA 相互作用:功能意义 翻译 > 翻译机制 RNA 在疾病与发育中的作用 > RNA 在疾病中的作用

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/895a/5763387/198ed22f9b21/WRNA-9-na-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/895a/5763387/198ed22f9b21/WRNA-9-na-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/895a/5763387/198ed22f9b21/WRNA-9-na-g001.jpg

相似文献

1
Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer.古今中外:提示一个核心转录后网络驱动卵巢癌化疗耐药。
Wiley Interdiscip Rev RNA. 2018 Jan;9(1). doi: 10.1002/wrna.1432. Epub 2017 Aug 1.
2
Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.Let-7 通过 IMP-1 介导的多药耐药蛋白 1 稳定化调节卵巢癌细胞对紫杉烷类药物获得性耐药。
Int J Cancer. 2012 Apr 15;130(8):1787-97. doi: 10.1002/ijc.26190. Epub 2011 Aug 16.
3
Translational remodeling by RNA-binding proteins and noncoding RNAs.RNA 结合蛋白和非编码 RNA 的转译重塑。
Wiley Interdiscip Rev RNA. 2021 Sep;12(5):e1647. doi: 10.1002/wrna.1647. Epub 2021 Mar 10.
4
Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.通过JNK-1/c-Jun途径上调顺铂耐药卵巢癌中miR-21的表达。
PLoS One. 2014 May 27;9(5):e97094. doi: 10.1371/journal.pone.0097094. eCollection 2014.
5
Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.RBPMS 水平降低可促进卵巢癌细胞增殖并降低顺铂敏感性。
Int J Mol Sci. 2022 Jan 4;23(1):535. doi: 10.3390/ijms23010535.
6
The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts.RNA 结合蛋白 SORBS2 通过稳定肿瘤抑制性免疫调节转录本抑制卵巢癌的转移性定植。
Genome Biol. 2018 Mar 16;19(1):35. doi: 10.1186/s13059-018-1412-6.
7
Circuitry of mRNA regulation.mRNA 调控回路。
Wiley Interdiscip Rev Syst Biol Med. 2010 Mar-Apr;2(2):245-251. doi: 10.1002/wsbm.55.
8
The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.长链非编码 RNA 对卵巢癌化疗反应的影响。
Gynecol Oncol. 2020 Mar;156(3):726-733. doi: 10.1016/j.ygyno.2019.12.020. Epub 2019 Dec 26.
9
Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.抑制 DDX39B 通过使 BRCA1 mRNA 不稳定来使卵巢癌细胞对 DNA 损伤化疗药物敏感。
Oncogene. 2020 Nov;39(47):7051-7062. doi: 10.1038/s41388-020-01482-x. Epub 2020 Sep 28.
10
Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression.环状 RNA circPBX3 通过与 IGF2BP2 相互作用稳定 ATP7A mRNA 的表达,促进卵巢癌细胞对顺铂的耐药性。
Hum Cell. 2022 Sep;35(5):1560-1576. doi: 10.1007/s13577-022-00748-8. Epub 2022 Jul 30.

引用本文的文献

1
Bioactive compounds from as potential inhibitors of RNA-binding protein La in ovarian cancer: a molecular modeling and quantum mechanics approach.来自[具体来源未提及]的生物活性化合物作为卵巢癌中RNA结合蛋白La的潜在抑制剂:一种分子建模和量子力学方法。
In Silico Pharmacol. 2024 Apr 20;12(1):32. doi: 10.1007/s40203-024-00202-7. eCollection 2024.
2
Immunogenic cell death-related gene landscape predicts the overall survival and immune infiltration status of ovarian cancer.免疫原性细胞死亡相关基因图谱可预测卵巢癌的总生存期和免疫浸润状态。
Front Genet. 2022 Nov 8;13:1001239. doi: 10.3389/fgene.2022.1001239. eCollection 2022.
3

本文引用的文献

1
PARP1 promotes gene expression at the post-transcriptiona level by modulating the RNA-binding protein HuR.PARP1 通过调节 RNA 结合蛋白 HuR 促进转录后水平的基因表达。
Nat Commun. 2017 Mar 8;8:14632. doi: 10.1038/ncomms14632.
2
Gene-microRNA network module analysis for ovarian cancer.卵巢癌的基因-微小RNA网络模块分析
BMC Syst Biol. 2016 Dec 23;10(Suppl 4):117. doi: 10.1186/s12918-016-0357-1.
3
RNA-binding protein RBM3 prevents NO-induced apoptosis in human neuroblastoma cells by modulating p38 signaling and miR-143.
RNA-binding proteins in ovarian cancer: a novel avenue of their roles in diagnosis and treatment.
RNA 结合蛋白在卵巢癌中的作用:其在诊断和治疗中的新途径。
J Transl Med. 2022 Jan 21;20(1):37. doi: 10.1186/s12967-022-03245-6.
4
RNA-binding proteins modulate drug sensitivity of cancer cells.RNA 结合蛋白调节癌细胞对药物的敏感性。
Emerg Top Life Sci. 2021 Nov 12;5(5):681-685. doi: 10.1042/ETLS20210193.
5
A New RBPs-Related Signature Predicts the Prognosis of Colon Adenocarcinoma Patients.一种新的与RNA结合蛋白相关的特征可预测结肠腺癌患者的预后。
Front Oncol. 2021 Mar 9;11:627504. doi: 10.3389/fonc.2021.627504. eCollection 2021.
6
Tumor-intrinsic and -extrinsic (immune) gene signatures robustly predict overall survival and treatment response in high grade serous ovarian cancer patients.肿瘤内在和外在(免疫)基因特征能够有力地预测高级别浆液性卵巢癌患者的总生存期和治疗反应。
Am J Cancer Res. 2021 Jan 1;11(1):181-199. eCollection 2021.
7
The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B.RNA结合蛋白CELF2通过稳定FAM198B抑制卵巢癌进展。
Mol Ther Nucleic Acids. 2020 Oct 15;23:169-184. doi: 10.1016/j.omtn.2020.10.011. eCollection 2021 Mar 5.
8
The Interplay between Long Noncoding RNAs and Proteins of the Epigenetic Machinery in Ovarian Cancer.长链非编码RNA与卵巢癌表观遗传机制蛋白之间的相互作用
Cancers (Basel). 2020 Sep 21;12(9):2701. doi: 10.3390/cancers12092701.
9
Tandem RNA isolation reveals functional rearrangement of RNA-binding proteins on 3'UTRs in cisplatin treated cells.串联 RNA 分离揭示了顺铂处理细胞中 RNA 结合蛋白在 3'UTR 上的功能重排。
RNA Biol. 2020 Jan;17(1):33-46. doi: 10.1080/15476286.2019.1662268. Epub 2019 Sep 16.
RNA 结合蛋白 RBM3 通过调节 p38 信号通路和 miR-143 预防一氧化氮诱导的人神经母细胞瘤细胞凋亡。
Sci Rep. 2017 Jan 30;7:41738. doi: 10.1038/srep41738.
4
Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR.miR-26a的持续表达通过调控CHFR促进染色体不稳定和肿瘤发生。
Nucleic Acids Res. 2017 May 5;45(8):4401-4412. doi: 10.1093/nar/gkx022.
5
Regulation of multidrug resistance by microRNAs in anti-cancer therapy.微小RNA在抗癌治疗中对多药耐药性的调控
Acta Pharm Sin B. 2017 Jan;7(1):38-51. doi: 10.1016/j.apsb.2016.09.002. Epub 2016 Dec 3.
6
Long noncoding RNA MALAT1-regulated microRNA 506 modulates ovarian cancer growth by targeting iASPP.长链非编码RNA MALAT1调控的微小RNA 506通过靶向iASPP来调节卵巢癌的生长。
Onco Targets Ther. 2016 Dec 19;10:35-46. doi: 10.2147/OTT.S112686. eCollection 2017.
7
A Feed-Forward Regulatory Loop between HuR and the Long Noncoding RNA HOTAIR Promotes Head and Neck Squamous Cell Carcinoma Progression and Metastasis.HuR与长链非编码RNA HOTAIR之间的前馈调节回路促进头颈部鳞状细胞癌的进展和转移。
Cell Physiol Biochem. 2016;40(5):1039-1051. doi: 10.1159/000453160. Epub 2016 Dec 12.
8
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.用于BRCA1/2突变型和散发性卵巢癌的PARP抑制剂:当前实践与未来方向
Br J Cancer. 2016 Nov 8;115(10):1157-1173. doi: 10.1038/bjc.2016.311. Epub 2016 Oct 13.
9
Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma.破坏MALAT1/miR-200c海绵体可降低子宫内膜样腺癌的侵袭和迁移能力。
Cancer Lett. 2016 Dec 1;383(1):28-40. doi: 10.1016/j.canlet.2016.09.019. Epub 2016 Sep 28.
10
Overexpression of long noncoding RNA, NEAT1 promotes cell proliferation, invasion and migration in endometrial endometrioid adenocarcinoma.长链非编码RNA NEAT1的过表达促进子宫内膜样腺癌的细胞增殖、侵袭和迁移。
Biomed Pharmacother. 2016 Dec;84:244-251. doi: 10.1016/j.biopha.2016.09.008. Epub 2016 Sep 21.